CLYM net incomeQ3 2026-$14.57M
CLYM net income was -$14.57M in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$12.89M a year earlier. For the full fiscal 2025 it was -$59.85M, compared with -$73.90M in fiscal 2024.
Climb Bio Inc. (CLYM) financials
For the twelve months ended Sep 30, 2026, Climb Bio Inc. reported -$59.31M of net income.
- Net income, TTM
- -$59.31M
- EPS, diluted, TTM
- -$0.81
- Cash
- $39.73M
- Market cap
- $646.7M
FY2023FY2024
FY2020FY2025
FY2023FY2025
CLYM revenue and earnings growth
CLYM EPSQ3 2026-$0.18
CLYM diluted EPS was -$0.18 in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$0.19 a year earlier. For the full fiscal 2025 it was -$0.88.
CLYM free cash flowQ3 2026-$12.82M
CLYM free cash flow was -$12.82M in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$12.25M a year earlier. For the full fiscal 2025 it was -$54.54M, compared with -$15.56M in fiscal 2024.
Income statement
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 |
|---|---|---|---|---|---|---|
| Revenue | - | $8.13M | $4.62M | - | - | - |
| Research and development | $46.71M | $14.34M | $15.41M | $26.21M | $23.32M | $8.77M |
| Selling, general and admin | $21.17M | $16.02M | $24.86M | $18.92M | $12.35M | $2.42M |
| Operating income | -$67.88M | -$82.02M | -$40.27M | -$45.13M | -$35.67M | -$20.93M |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$59.85M | -$73.90M | -$35.12M | -$45.24M | -$47.48M | -$20.67M |
| EPS, basic | -$0.88 | -$1.53 | -$1.30 | -$1.72 | -$4.24 | -$10.49 |
| EPS, diluted | -$0.88 | -$1.53 | -$1.30 | -$1.72 | -$4.24 | -$10.49 |
| Diluted shares | 67.8M | 48.2M | 27.0M | 26.3M | 12.3M | 2.2M |
Balance sheet
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 |
|---|---|---|---|---|---|---|
| Cash and equivalents | $35.69M | $87.23M | $93.11M | $43.59M | $46.92M | $20.49M |
| Short-term investments | $65.39M | $63.69M | $13.69M | $79.98M | $89.56M | $0 |
| Current assets | $105.85M | $154.87M | $110.25M | $134.39M | $148.25M | $22.00M |
| Total assets | $167.74M | $217.19M | $110.47M | $134.99M | $173.24M | $24.63M |
| Current liabilities | $6.98M | $4.93M | $2.83M | $6.10M | $6.03M | $3.06M |
| Total liabilities | $7.27M | $5.31M | $2.87M | $6.28M | $6.04M | $3.06M |
| Shareholders' equity | $160.47M | $211.88M | $107.60M | $128.72M | $167.20M | -$24.98M |
Cash flow
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$54.36M | -$15.56M | -$20.60M | -$37.37M | -$36.07M | -$14.10M |
| Capital expenditures | $186.0K | $0 | $0 | - | - | - |
| Free cash flow | -$54.54M | -$15.56M | -$20.60M | - | - | - |
| Investing cash flow | $2.83M | -$121.09M | $68.98M | $34.44M | -$114.97M | $8.08M |
| Financing cash flow | -$21.0K | $130.73M | $841.0K | $0 | $177.23M | $4.92M |
| Stock-based compensation | $8.05M | $5.56M | $12.81M | $6.99M | $3.74M | $707.0K |
| Depreciation and amortization | $97.0K | $0 | - | - | - | - |
Key ratios
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 |
|---|---|---|---|---|---|---|
| Revenue growth, YoY | - | 76.0% | - | - | - | - |
| Operating margin | - | -1008.6% | -871.8% | - | - | - |
| Net margin | - | -908.7% | -760.2% | - | - | - |
| Free cash flow margin | - | -191.4% | -445.9% | - | - | - |
| Return on equity | -37.3% | -34.9% | -32.6% | -35.2% | -28.4% | - |
| Return on assets | -35.7% | -34.0% | -31.8% | -33.5% | -27.4% | -83.9% |
| Current ratio | 15.16 | 31.41 | 38.92 | 22.04 | 24.58 | 7.18 |
Income statement
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Research and development | $11.04M | $9.71M | $9.37M | $13.74M | $9.07M | $6.58M | $17.33M | $5.96M | $6.24M | $1.05M | $1.09M | $3.13M |
| Selling, general and admin | $5.85M | $5.64M | $5.84M | $5.56M | $5.82M | $4.10M | $5.69M | $4.95M | $5.49M | $3.67M | $1.91M | $2.00M |
| Operating income | -$16.89M | -$15.36M | -$15.21M | -$19.30M | -$14.89M | -$10.68M | -$23.02M | -$10.91M | -$11.73M | -$56.37M | -$3.00M | -$5.12M |
| Income tax | - | - | - | - | - | - | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$14.57M | -$13.50M | -$13.72M | -$17.52M | -$12.89M | -$8.67M | -$20.78M | -$8.42M | -$8.89M | -$54.89M | -$1.70M | -$3.64M |
| EPS, basic | -$0.18 | -$0.18 | -$0.20 | -$0.25 | -$0.19 | -$0.13 | -$0.31 | - | -$0.13 | -$1.81 | -$0.06 | -$0.12 |
| EPS, diluted | -$0.18 | -$0.18 | -$0.20 | -$0.25 | -$0.19 | -$0.13 | -$0.31 | - | -$0.13 | -$1.81 | -$0.06 | -$0.12 |
| Diluted shares | 80.0M | 76.2M | 68.2M | - | 68.0M | 67.6M | 67.5M | - | 67.0M | 30.3M | 27.6M | - |
Balance sheet
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $39.73M | $44.11M | $8.36M | $35.69M | $25.80M | $22.68M | $29.02M | $87.23M | $146.18M | $223.14M | $105.03M | $93.11M |
| Short-term investments | $165.69M | $139.02M | $101.21M | $65.39M | $61.10M | $62.02M | $69.04M | $63.69M | $47.18M | $0 | $0 | $13.69M |
| Current assets | $210.15M | $186.64M | $113.40M | $105.85M | $90.96M | $87.38M | $100.28M | $154.87M | $197.61M | $226.00M | $109.22M | $110.25M |
| Total assets | $236.56M | $246.29M | $152.37M | $167.74M | $182.30M | $192.39M | $200.74M | $217.19M | $222.20M | $226.02M | $109.33M | $110.47M |
| Current liabilities | $7.91M | $5.93M | $4.07M | $6.98M | $4.95M | $6.21M | $7.04M | $4.93M | $3.42M | $3.74M | $2.95M | $2.83M |
| Total liabilities | $8.51M | $6.75M | $4.29M | $7.27M | $5.30M | $6.62M | $7.36M | $5.31M | $3.42M | $3.74M | $2.95M | $2.87M |
| Shareholders' equity | $228.05M | $239.55M | $148.09M | $160.47M | $177.00M | $185.76M | $193.38M | $211.88M | $218.78M | $222.28M | $106.38M | $107.60M |
Cash flow
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$12.00M | -$10.55M | -$14.38M | -$15.63M | -$12.14M | -$11.15M | -$15.43M | -$5.52M | -$7.55M | -$667.0K | -$1.82M | -$947.0K |
| Capital expenditures | $820.0K | - | - | $0 | $109.0K | - | - | $0 | $0 | - | - | $0 |
| Free cash flow | -$12.82M | - | - | -$15.63M | -$12.25M | - | - | -$5.52M | -$7.55M | - | - | -$947.0K |
| Investing cash flow | $6.40M | -$57.26M | -$12.96M | $25.54M | $15.26M | $4.79M | -$42.75M | -$53.41M | -$71.79M | -$9.64M | $13.75M | $36.75M |
| Financing cash flow | $1.22M | $103.70M | $5.0K | -$21.0K | $0 | $0 | $0 | $41.0K | $2.27M | $128.40M | $15.0K | $288.0K |
| Stock-based compensation | $2.04M | $1.48M | $1.60M | $1.04M | $3.98M | $1.01M | $2.02M | $1.66M | $2.92M | $512.0K | $465.0K | $1.20M |
| Depreciation and amortization | $195.0K | $33.0K | $38.0K | $30.0K | $29.0K | $38.0K | $0 | $0 | $0 | - | - | - |
Key ratios
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current ratio | 26.58 | 31.45 | 27.86 | 15.16 | 18.38 | 14.08 | 14.25 | 31.41 | 57.73 | 60.41 | 37.02 | 38.92 |
Source: XBRL data Climb Bio Inc. files with the SEC, latest filing dated Nov 5, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures are as filed. The filings show no stock split in these periods.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
CLYM peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| CLYM | - | - | -$59.31M | - | $646.7M |
| LLY | $86.46B | +45.5% | $27.58B | 31.9% | $1.33T |
| JNJ | $99.33B | +7.8% | $16.09B | 16.2% | $679.13B |
| ABBV | $66.01B | +10.7% | $10.34B | 15.7% | $518.44B |
| MRK | $67.38B | +4.9% | $2.45B | 3.6% | $366.73B |
| NVS | $54.53B | +8.4% | $13.98B | 25.6% | $312.35B |
| AZN | $58.74B | +8.6% | $10.22B | 17.4% | $293.69B |
| ABT | $48.23B | +10.0% | $4.70B | 9.7% | $191.40B |
| NVO | DKK 309.06B | +6.4% | DKK 102.43B | 33.1% | $183.23B |
CLYM FAQ
5 questionsIs CLYM profitable?
No. Climb Bio Inc. reported a net loss of $59.31M for the twelve months ended Sep 30, 2026.How much cash and debt does CLYM have?
Climb Bio Inc. reported $39.73M in cash and cash equivalents on its most recent balance sheet in SEC filings.What is CLYM earnings per share?
Diluted earnings per share were -$0.81 for the twelve months ended Sep 30, 2026, from SEC filings, restated for any stock split those filings show.When did CLYM last report financial results?
The latest statements here come from Climb Bio Inc.'s 10-Q filed on Nov 5, 2026, covering the period ended Sep 30, 2026.Where does this CLYM financial data come from?
Quantisnow builds these statements from the structured XBRL data Climb Bio Inc. files with the SEC. It is provided for information only and is not investment advice.